381.02MMarket Cap-1.90P/E (TTM)
0.000High0.000Low0Volume0.000Open3.650Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)104.39MShares7.56052wk High-2.34P/B328.76MFloat Cap2.30052wk Low--Dividend TTM90.07MShs Float42.410Historical High--Div YieldTTM0.00%Amplitude2.300Historical Low--Avg Price1Lot Size
Revance Therapeutics(Delisted) Stock Forum
Major Aesthetics Deal: Crown Labs Acquires Revance as Shareholders Cash Out at Premium
Major Biotech Deal: Revance Shareholders Back Crown Labs Takeover with Massive 82% Support Rate
Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.
Monday, 13th January at 8:30 am
JOHNSON CITY, Tenn., Jan. 13, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that, at the request of Revance Therapeutics, Inc., ("Revance") (NASDAQ: RVNC), it has extended the expiration of its cash tender offer to acquire all of the issued and outstand...
Dow Jones· 1 min ago
Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash
Monday, 6th January at 9:00 am
Compelling Cash Proposal Provides 16% Premium Over Revance's Amended and Restated Agreement with Crown Laboratories
GENEVA, Jan. 6, 2025 /PRNewswire/ -- Teoxane SA today announced that on January 6, 2025, it submitted a proposal to the Board of Directors of Revance Therapeutics, Inc. (NASDAQ: RVNC) to acquire Revance for $3.60 per s...
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
No comment yet